BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 33199228)

  • 1. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Asahina H; Tanaka K; Morita S; Maemondo M; Seike M; Okamoto I; Oizumi S; Kagamu H; Takahashi K; Kikuchi T; Isobe T; Sugio K; Kobayashi K
    Clin Lung Cancer; 2021 Mar; 22(2):147-151. PubMed ID: 33199228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
    Papadimitrakopoulou VA; Mok TS; Han JY; Ahn MJ; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y; Akamatsu H; Theelen WSME; Su WC; John T; Sebastian M; Mann H; Miranda M; Laus G; Rukazenkov Y; Wu YL
    Ann Oncol; 2020 Nov; 31(11):1536-1544. PubMed ID: 32861806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
    Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.
    Planchard D; Feng PH; Karaseva N; Kim SW; Kim TM; Lee CK; Poltoratskiy A; Yanagitani N; Marshall R; Huang X; Howarth P; Jänne PA; Kobayashi K
    ESMO Open; 2021 Oct; 6(5):100271. PubMed ID: 34543864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
    Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
    Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
    JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
    Mok TS; Wu Y-L; Ahn M-J; Garassino MC; Kim HR; Ramalingam SS; Shepherd FA; He Y; Akamatsu H; Theelen WS; Lee CK; Sebastian M; Templeton A; Mann H; Marotti M; Ghiorghiu S; Papadimitrakopoulou VA;
    N Engl J Med; 2017 Feb; 376(7):629-640. PubMed ID: 27959700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib with or without Chemotherapy in
    Planchard D; Jänne PA; Cheng Y; Yang JC; Yanagitani N; Kim SW; Sugawara S; Yu Y; Fan Y; Geater SL; Laktionov K; Lee CK; Valdiviezo N; Ahmed S; Maurel JM; Andrasina I; Goldman J; Ghiorghiu D; Rukazenkov Y; Todd A; Kobayashi K;
    N Engl J Med; 2023 Nov; 389(21):1935-1948. PubMed ID: 37937763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
    John T; Akamatsu H; Delmonte A; Su WC; Lee JS; Chang GC; Huang X; Jenkins S; Wu YL
    Lung Cancer; 2018 Dec; 126():133-138. PubMed ID: 30527177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
    Wu YL; Ahn MJ; Garassino MC; Han JY; Katakami N; Kim HR; Hodge R; Kaur P; Brown AP; Ghiorghiu D; Papadimitrakopoulou VA; Mok TSK
    J Clin Oncol; 2018 Sep; 36(26):2702-2709. PubMed ID: 30059262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
    Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Kogure Y; Tachihara M; Fujimoto D; Yamaguchi K; Hamaguchi N; Okamoto I; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2021 Jul; 22(4):376-380. PubMed ID: 33612406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
    Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
    Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
    Saito R; Sugawara S; Ko R; Azuma K; Morita R; Maemondo M; Oizumi S; Takahashi K; Kagamu H; Tsubata Y; Seike M; Kikuchi T; Okamoto I; Satoshi M; Asahina H; Tanaka K; Sugio K; Kobayashi K
    Eur J Cancer; 2023 May; 185():83-93. PubMed ID: 36966696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
    La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
    J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer.
    Jänne PA; Planchard D; Kobayashi K; Cheng Y; Lee CK; Valdiviezo N; Laktionov K; Yang TY; Yu Y; Kato T; Jiang L; Chewaskulyong B; Lucien Geater S; Maurel JM; Rojas C; Takahashi T; Havel L; Shepherd FA; Tanaka K; Ghiorghiu D; Amin NP; Armenteros-Monterroso E; Huang X; Chaudhry AA; Yang JC
    J Clin Oncol; 2024 Mar; 42(7):808-820. PubMed ID: 38042525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
    Guan H; Liu G; Xie F; Sheng Y; Shi L
    Clin Ther; 2019 Nov; 41(11):2308-2320.e11. PubMed ID: 31607559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
    Uchibori K; Satouchi M; Sueoka-Aragane N; Urata Y; Sato A; Imamura F; Inoue T; Tachihara M; Kobayashi K; Katakami N; Kokan C; Hirashima T; Iwanaga K; Mori M; Aoe K; Morita S; Negoro S
    Lung Cancer; 2018 Oct; 124():65-70. PubMed ID: 30268482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment.
    Acker F; Aguinarte L; Althoff F; Heinzen S; Rost M; Wild P; Reiser L; Mänz M; Meyer F; Stratmann J; Sebastian M
    Clin Lung Cancer; 2022 Nov; 23(7):e473-e477. PubMed ID: 36089483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.